Oppenheimer analyst Mark Breidenbach lowered the firm’s price target on Iovance Biotherapeutics to $15 from $25 and keeps an Outperform rating on the shares following quarterly results. The firm notes management still believes lifileucel’s BLA is on track for a March filing, which could potentially support accelerated approval in 2L+ advanced melanoma in Q4.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IOVA:
- Iovance Biotherapeutics to Present at Upcoming Conferences
- Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
- Iovance Biotherapeutics reports Q4 EPS (64c), consensus (64c)
- Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023
- IOVA Up after Analyst Upgrade
